STOCK TITAN

Yarrow Bioscience: venBio reports roughly 9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Yarrow Bioscience, Inc. (YARW) reported that venBio Global Strategic Fund V, L.P. and its general partner, venBio Global Strategic GP V, LLC, may each be deemed to beneficially own 1,211,820 common shares, approximately 9.99%, as of September 30, 2026. Fund V directly held 554,769 shares and 3,434,702 Pre-Funded Warrants; 657,051 shares acquirable within 60 days upon warrant exercise were included in the reported beneficial ownership.

Exercise is limited if it would cause the reporting entities and their affiliates, when aggregated, to own more than 9.99% immediately after exercise. The cap may be increased up to 19.99%, but any increase would not take effect until the 61st day after written notice is delivered to Yarrow Bioscience. The company had 11,473,285 common shares outstanding as of September 30, 2026.

Beneficial ownership 1,211,820 shares Each reporting entity may be deemed to own this amount as of September 30, 2026.
Common shares directly held 554,769 shares Held directly by venBio Global Strategic Fund V, L.P.
Shares acquirable through warrants 657,051 shares Acquirable within 60 days upon exercise of Pre-Funded Warrants, subject to the Blocker.
Pre-Funded Warrants held 3,434,702 warrants Held directly by venBio Global Strategic Fund V, L.P.
Beneficial ownership percentage Approximately 9.99% Each reporting entity's reported percentage as of September 30, 2026.
Common shares outstanding 11,473,285 shares Outstanding as of September 30, 2026.
Potential increased ownership cap Up to 19.99% Any increase would not take effect until the 61st day after written notice is delivered to the issuer.
Pre-Funded Warrants financial
"shares Fund V has the right to acquire within 60 days upon exercise of Pre-Funded Warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Blocker financial
"subject to the Blocker"
beneficial ownership regulatory
"may be deemed to beneficially own 1,211,820 shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Rule 13d-3(d)(1)(i) regulatory
"in accordance with Rule 13d-3(d)(1)(i) under the Exchange Act"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many YARW shares did venBio report beneficially owning?

Each of venBio Global Strategic Fund V, L.P. and its general partner, venBio Global Strategic GP V, LLC, may be deemed to beneficially own 1,211,820 shares, or approximately 9.99%, as of September 30, 2026. The entities report the same amount; these figures are not additive.

What is the YARW warrant ownership cap, and can it change?

The cap prevents warrant exercise to the extent it would cause the reporting entities and their affiliates, when required to aggregate ownership, to own more than 9.99% immediately after exercise. It may be increased up to 19.99%, with an increase effective on the 61st day after written notice is delivered to Yarrow Bioscience.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





92941V407

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



venBio Global Strategic Fund V, L.P.
Signature:/s/ David Pezeshki
Name/Title:David Pezeshki, as attorney-in-fact for Aaron Royston, Corey Goodman, and Richard Gaster, Members of the General Partner
Date:11/16/2026
venBio Global Strategic GP V, LLC
Signature:/s/ David Pezeshki
Name/Title:David Pezeshki, as attorney-in-fact for Aaron Royston, Corey Goodman, and Richard Gaster, Members
Date:11/16/2026

Comments accompanying signature: This Schedule 13G was executed by David Pezeshki on behalf of the individuals listed above pursuant to a Power of Attorney, copies of which are attached as Exhibit 2 and Exhibit 3 to the Schedule 13G.
Exhibit Information

Exhibit 1: Joint Filing Agreement Exhibit 2: Power of Attorney regarding filings under the Exchange Act Exhibit 3: Power of Attorney regarding filings under the Exchange Act

Keep reading